TNF and rheumatoid arthritis: Currently, five classes of molecular targeted therapies are available for rheumatoid arthritis, each focused on specific biological targets: the cytokines TNF (tumor necrosis factor) and IL‐6 (interleukin‐6), mechanisms of T‐cell activation, CD19 positive B cells, and the tyrosine kinase JAK (Janus kinase).